Celcuity’s Promising Phase 3 Trial and Strong Market Position: A Buy Recommendation

In a report released today, Oliver McCammon from LifeSci Capital maintained a Buy rating on Celcuity (CELC – Research Report), with a price target of $27.00.

Oliver McCammon’s rating is based on the promising developments in Celcuity’s ongoing Phase 3 VIKTORIA-1 trial, which is testing their pan-PI3K/mTOR inhibitor, gedatolisib, in combination with Pfizer’s CDK4/6 inhibitor and a selective estrogen receptor degrader. The trial targets ER+ breast cancer patients, and the company is projecting a primary completion date for the PIK3CA WT cohort in June, with topline data expected in Q3 2025. This timeline suggests potential positive outcomes that could enhance Celcuity’s market position.
Furthermore, McCammon highlights the competitive landscape, noting that recent data from Eli Lilly’s EMBER-3 trial has not met expectations, particularly in terms of progression-free survival. This underwhelming performance by a competitor underscores the potential for Celcuity’s treatment to stand out in the market. Additionally, Celcuity’s financial position, with a cash runway of approximately two years, supports their ongoing research and development efforts, making the stock an attractive buy.